Androgen receptor mRNA (hinge region) (AR mRNA)

The Androgen receptor (AR) mRNA hinge region, specifically encoded by exon 4 of the AR gene, is a therapeutic target for antisense oligonucleotides (ASOs) designed to treat advanced prostate cancer (PubMed: 23471015). The hinge region of the AR protein is crucial for its nuclear translocation and DNA-binding stability, making the corresponding mRNA sequence a high-value site for gene silencing (Cancer Res, 2011). Therapeutic agents like EZN-4176, a Locked Nucleic Acid (LNA)-based ASO, are engineered to bind specifically to this region, triggering RNase H-mediated degradation of the mRNA transcript. This process results in the depletion of full-length AR protein, thereby inhibiting the androgen signaling axis that drives tumor progression in castration-resistant prostate cancer (CRPC) (Clin Cancer Res, 2013). While this strategy effectively targets full-length AR, it may be bypassed by certain AR splice variants, such as AR-V7, which lack exon 4 and remain constitutively active (Oncotarget, 2016). Consequently, the hinge region target represents a sophisticated approach to overcoming resistance to traditional androgen deprivation therapies, though it requires careful patient selection based on AR variant profiles.

Other names

AR mRNA exon 4NR3C4 mRNAAndrogen receptor transcript hinge region

Antisense oligonucleotide-mediated RNase H recruitment and subsequent degradation of the target mRNA transcript, preventing translation of the androgen receptor protein.